Pharmaceutical composition for preventing or treating cancer

A pharmaceutical composition using CD4+ CTLs activated by cytokines addresses the limitations of existing immunotherapies by enhancing cytotoxicity and predicting prognosis in multiple myeloma through NKG2D+ CD4+ CTL ratio measurement, improving treatment outcomes.

WO2026095708A1 Publication Date: 2026-05-07UI (UNIVERSITY IND FOUNDATION) YONSEI UNIVERSITY
2 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2025/017698
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-10-31
Filing Date
2025-10-31
Publication Date
2026-05-07

AI Technical Summary

Technical Problem

Existing immunotherapies for multiple myeloma, such as those using chimeric antigen receptors (CARs) or bispecific antibodies, face limitations including non-sustained responses and frequent relapses, highlighting the need for further research into the functional characteristics of effector T cells, particularly CD4+ CTLs, which are traditionally known for helper or regulatory functions but possess cytotoxicity in hematological cancers.

Method used

A pharmaceutical composition comprising CD4+ CTLs as an active ingredient, activated via cytokines, and a method to measure the ratio of NKG2D+ CD4+ CTLs to predict cancer prognosis and provide information on progression-free survival.

Benefits of technology

The composition effectively activates CD4+ CTL cytotoxicity and predicts cancer prognosis by measuring NKG2D+ CD4+ CTL ratios, enhancing treatment efficacy and progression-free survival in multiple myeloma patients.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating cancer, the pharmaceutical composition containing CD4+ CTL as an active ingredient. The CD4+ CTL according to the present invention performs a cytotoxic function of directly attacking and killing myeloma cells, thereby extending the progression-free survival of transplant-ineligible myeloma patients, and thus can contribute to increasing the survival rate of the patients. In addition, by using NKG2D+ CD4+ CTL as a biomarker for predicting the prognosis of myeloma patients, it is possible to analyze the CD4+ CTL status of individual patients and thereby establish customized treatment strategies. In addition, by increasing the cytotoxicity of NKG2D+ CD4+ CTL through a specific cytokine treatment, it is possible to more effectively prevent or treat cancer.
Need to check novelty before this filing date? Find Prior Art